Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
Abivax (ABVX) has announced a Key Opinion Leader (KOL) Investor Webcast scheduled for March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET). The virtual event will feature Professor David T. Rubin, MD, Chief of Gastroenterology at The University of Chicago and Director of their Inflammatory Bowel Disease Center.
The webcast will focus on the ulcerative colitis (UC) treatment landscape and Abivax's ABTECT Phase 3 trial of obefazimod in adults with moderately to severely active UC. Dr. Rubin will discuss obefazimod's potential to address unmet medical needs in UC treatment.
The event will conclude with a live Q&A session featuring Dr. Rubin and Abivax's management team. Interested participants can register for the webcast through the provided link: https://lifescievents.com/event/abivax-3/.
Abivax (ABVX) ha annunciato un webcast per investitori con un Key Opinion Leader (KOL) programmato per il 17 marzo 2025, alle 9:00 EDT (14:00 CET). L'evento virtuale presenterà il Professor David T. Rubin, MD, Capo di Gastroenterologia presso l'Università di Chicago e Direttore del loro Centro per le Malattie Infiammatorie Intestinali.
Il webcast si concentrerà sul panorama del trattamento della colite ulcerosa (UC) e sul trial di fase 3 ABTECT di obefazimod negli adulti con UC moderatamente a gravemente attiva. Il Dr. Rubin discuterà del potenziale di obefazimod per soddisfare i bisogni medici non ancora soddisfatti nel trattamento della UC.
L'evento si concluderà con una sessione di domande e risposte dal vivo con il Dr. Rubin e il team di gestione di Abivax. I partecipanti interessati possono registrarsi per il webcast tramite il link fornito: https://lifescievents.com/event/abivax-3/.
Abivax (ABVX) ha anunciado un webcast para inversores con un Líder de Opinión Clave (KOL) programado para el 17 de marzo de 2025, a las 9:00 a.m. EDT (2:00 p.m. CET). El evento virtual contará con el Profesor David T. Rubin, MD, Jefe de Gastroenterología en la Universidad de Chicago y Director de su Centro de Enfermedades Inflamatorias Intestinales.
El webcast se centrará en el panorama del tratamiento de la colitis ulcerosa (UC) y en el ensayo de fase 3 ABTECT de obefazimod en adultos con UC moderadamente a gravemente activa. El Dr. Rubin discutirá el potencial de obefazimod para abordar las necesidades médicas no satisfechas en el tratamiento de la UC.
El evento concluirá con una sesión de preguntas y respuestas en vivo con el Dr. Rubin y el equipo directivo de Abivax. Los participantes interesados pueden registrarse para el webcast a través del enlace proporcionado: https://lifescievents.com/event/abivax-3/.
Abivax (ABVX)는 2025년 3월 17일 오전 9시 EDT (오후 2시 CET)에 예정된 투자자 웹캐스트를 발표했습니다. 이 가상 이벤트에는 시카고 대학교 소화기내과장인 David T. Rubin 교수, MD가 참여합니다.
웹캐스트는 궤양성 대장염 (UC) 치료 환경과 성인에서 중등도에서 중증으로 활동적인 UC에 대한 obefazimod의 ABTECT 3상 시험에 초점을 맞출 것입니다. Rubin 박사는 UC 치료에서 충족되지 않은 의료 요구를 해결하기 위한 obefazimod의 잠재력에 대해 논의할 것입니다.
이벤트는 Rubin 박사와 Abivax 경영진이 함께하는 라이브 Q&A 세션으로 마무리됩니다. 관심 있는 참가자는 제공된 링크를 통해 웹캐스트에 등록할 수 있습니다: https://lifescievents.com/event/abivax-3/.
Abivax (ABVX) a annoncé un webcast pour investisseurs avec un Leader d'Opinion Clé (KOL) prévu pour le 17 mars 2025, à 9h00 EDT (14h00 CET). L'événement virtuel mettra en vedette le Professeur David T. Rubin, MD, Chef de la Gastroentérologie à l'Université de Chicago et Directeur de leur Centre des Maladies Inflammatoires de l'Intestin.
Le webcast se concentrera sur le paysage du traitement de la colite ulcéreuse (UC) et sur l'
L'événement se terminera par une session de questions-réponses en direct avec le Dr Rubin et l'équipe de direction d'Abivax. Les participants intéressés peuvent s'inscrire au webcast via le lien fourni : https://lifescievents.com/event/abivax-3/.
Abivax (ABVX) hat ein Investor-Webcast mit einem Key Opinion Leader (KOL) für 17. März 2025, um 9:00 Uhr EDT (14:00 Uhr CET) angekündigt. Die virtuelle Veranstaltung wird Professor David T. Rubin, MD, Leiter der Gastroenterologie an der Universität von Chicago und Direktor ihres Zentrums für entzündliche Darmerkrankungen, präsentieren.
Der Webcast wird sich auf die Behandlungsmöglichkeiten der colitis ulcerosa (UC) und die ABTECT Phase 3 Studie von obefazimod bei Erwachsenen mit moderat bis schwer aktiver UC konzentrieren. Dr. Rubin wird das Potenzial von obefazimod zur Deckung ungedeckter medizinischer Bedürfnisse in der UC-Behandlung erörtern.
Die Veranstaltung wird mit einer Live-Q&A-Sitzung mit Dr. Rubin und dem Management-Team von Abivax enden. Interessierte Teilnehmer können sich über den bereitgestellten Link für den Webcast registrieren: https://lifescievents.com/event/abivax-3/.
- None.
- None.
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax’s Pivotal ABTECT Phase 3 Trial
PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET).
The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease Center at The University of Chicago. Dr. Rubin will provide expert insights into the evolving treatment landscape for ulcerative colitis (UC) and discuss expectations for Abivax’s ABTECT Phase 3 trial evaluating obefazimod in adults with moderately to severely active UC. He will also explore obefazimod’s potential to address critical unmet medical needs in UC treatment.
Following the presentation, attendees will have the opportunity to participate in a live Q&A session with Dr. Rubin and Abivax’s management team.
Event Details:
Date: Monday, March 17, 2025
Time: 9:00 a.m. EDT | 2:00 p.m. CET
Format: Virtual webcast
Registration Details:
To register for the webcast and access further event details, please click on this link https://lifescievents.com/event/abivax-3/.
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX.
Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878
FAQ
When is Abivax (ABVX) hosting its KOL webcast on ulcerative colitis treatment?
What will be discussed in Abivax's March 2025 KOL webcast?
Who is the key speaker at Abivax's March 2025 investor webcast?
What is the focus of Abivax's ABTECT Phase 3 trial?
How can investors participate in Abivax's March 2025 KOL webcast?
